MOGUĆNOST KORIŠĆENJA BIOHEMIJSKIH I HEMATOLOŠKIH PARAMETARA U PROCENI ADNEKSALNIH MASA
Sažetak
Sadašnji dijagnostički pristup adneksalnim masama (anamneza, klinički pregled, transvaginalna sonografija, tumorski markeri) ne omogućava preciznu predikciju mogućeg maligniteta. Postoji mogućnost korišćenja hematoloških i biohemijskih parametara (broj trombocita, odnos neutrofila i limfocita, odnos trombocita i neutrofila, trombocitna širina, nivo C reaktivnog proteina) u predikciji ovarijalnog maligniteta.
Sprovedeno je retrospektivno istraživanje. Analiza pomenutih parametara kod bolesnica sa histopatološki verifikovanim benignim/malignim ovarijalnim tumorima.
Vrednosti CRP-a, ukupan broj granulocita i ukupan broj trombocita statistički su značajno veće kod bolesnica sa malignim promenama (p < 0,001, p = 0,001; odnosno p = 0,023). Ukupan broj limfocita statistički je značajno manji kod bolesnica sa malignim promenama (p < 0,001). Broj trombocita statistički je značajno veći kod bolesnica sa stadijumom III tumora (p = 0,011). Odnos Tr/LY statistički je značajno veći kod bolesnica sa stadijumom III tumora (p = 0,043). CRP je statistički značajno viši kod bolesnica III stadijuma tumora (p < 0,001). Broj limfocita statistički je značajno niži kod bolesnica III stadijuma tumora (p < 0,001), a broj granulocita je statistički značajno veći kod bolesnica sa III stadijumom tumora (p = 0,001). Broj trombocita statistički je značajno veći kod bolesnica sa III stadijumom tumora (p = 0,001). MPV je statistički značajno manji kod bolesnica sa III stadijumom tumora (p = 0,031). Tr/Ly odnos statistički je značajno veći kod bolesnica na III stadijumom tumora (p = 0,044).
Ispitivani biohemijski i hematološki parametri su od ograničene vrednosti u diferenci-jaciji benignih od malignih ovarijalnih masa. Povišeni nivoi C reaktivnog proteina, neutrofila i trombocita ukazuju na, verovatno, malignu ovarijalnu masu. Ispitivani biohemijski parametri (visoki nivoi C reaktivnog proteina, nizak broj limfocita, viši broj granulocita, viši niovoi trombocita, povišeni odnos PLR-a, kao i niži nivoi MPV-a) mogu ukazati na uznapredovalu malignu bolest.
Reference
Amor F, Alcázar JL, Vaccaro H, León M, Iturra A. GIRADS reporting system for ultrasound evaluation of adnexal masses in clinical practice: a prospective multicenter study. Ultrasound Obstet Gynecol 2011; 38(4):450-5. [CrossRef] [PubMed]
Bakacak M, Serin S, Ercan Ö, Köstü B, Bostancı MS, Bakacak Z et al. Utility of preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios to dis-tinguish malignant from benign ovarian masses. J Turk Ger Gynecol Assoc 2016;17(1):21-5. [CrossRef] [PubMed]
Bednarska K, Król E, Głowacka E, Romanowicz H, Szyłło K, Klink M et al. Analysis of preoperative blood platelet parameters in terms of diversity of epithelial ovarian cancer. Medicine (Baltimore) 2018;97(12): 0180. [CrossRef] [PubMed]
Behnamfar F, Adibi A, Khadra H, Moradi M. Diagnostic accuracy of gynecology imaging reporting and data system in evaluation of adnexal lesions. J Res Med Sci 2019;24:57. [CrossRef] [PubMed]
Biggs WS, Marks ST. Diagnosis and Management of Adnexal Masses. Am Fam Physician 2016;93(8):676-81. [PubMed]
Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, Fahey A, et al. Effect of surgeon specialty on pro-cesses of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 2006;98:172-80. [CrossRef] [PubMed]
Giede KC, Kieser K, Dodge J, Rosen B. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol 2005;99:447-61. [CrossRef] [PubMed]
Glanc P, Benacerraf B, Bourne T, Brown D, Coleman BG, Crum C et al. First International Consensus Report on Adnexal Masses: Management Recommendations. J Ultrasound Med 2017;36(5):849-63. [CrossRef] [PubMed]
Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumor-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011;105(1):93-103. [CrossRef] [PubMed]
Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ.The systemic inflammation-based neutrophil-lymphocyte ratio: experience in pa-tients with cancer. Crit Rev Oncol Hematol 2013; 88(1):218-30. [CrossRef] [PubMed]
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646-74. [CrossRef] [PubMed]
Kokanalı MK, Cavkaytrar S, Bozkurt S, Türker M, Aydın F, Doğanay M. Misdiagnosis of a Right Adnexal Mass: A Peculiar Case of Benign Appendiceal Muco-cele. J Gynecol Surg 2016;32(1):51-3. [CrossRef]
Krleža L, Zadro R, Nakić M, Sucic M, Huzjak N, Jurucevic M et al. Significance and usefulness of platelets indexes. Paediatria croatica 1999;43(2):79-85.
Migda M, Bartosz M, Migda MS, Kierszk M, Katarzyna G, Maleńczyk M. Diagnostic value of the gynecology imaging reporting and data system (GI-RADS) with the ovarian malignancy marker CA-125 in pre-operative adnexal tumor assessment. J Ovarian Res 2018;11(1):92. [CrossRef] [PubMed]
Naik R, Galaal K, Alagoda B, Katory M, Mercer-Jones M, Farrel R. Surgical training in gastrointestinal procedures within a UK gynaecological oncology sub-specialty programme. BJOG 2010;117:26-31. [CrossRef] [PubMed]
Petric A, Tubic Pavlovic A, Djordjevic I, Vucetic D, Zivadinovic R, Krtinic et al. Echinococcosis of Iliopsoas Muscle and Anaphylaxis as the Cause of Urgent Laparotomy. West Indian Med J 2014;1(3):111-3.
Petrie HT, Klassen LW, Kay HD . Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. J Immunol 1985; 134(1):230-4. [PubMed]
Prodromidou A, Andreakos P, Kazakos C, Vlachos DE, Perrea D, Pergialiotis V. The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-tolym-phocyte ratio in ovarian cancer. Inflamm Res 2017; 66(6):467-75. [CrossRef] [PubMed]
Sah SK, Shi X, Silin D, Li X, Shah S, Shresta K et al. CT findings and analysis for misdiagnosis of female pelvic tuberculosis. Radiol Infect Dis 2017;4(1):19-25. [CrossRef]
Sylman JL, BoyceHB, Mitrugno A, Tormoen GW, Tomas IC, Wgner TH. Temporal Examination of Pla-telet Counts as a Predictor of Prognosis in Lung, Prostate, and Colon Cancer Patients. 2018;SciRep(8): 6564. [CrossRef] [PubMed]
Templeton AJ, McNamara MG, Šeruga B, Vera Badillo FE, Aneja P, Ocaña A et al. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. JNCI 2014; 106(6):124. [CrossRef] [PubMed]
Thakur M, Thakur A, Mahajan K, Rathore S, Jindal A, Gupta G. An Interesting Case of Misdiagnosed Adnexal Mass. ASMS 2018;2(1):30-32.
Tian C, Song W, Tian X, Sun Y. Prognostic significance of platelet-to-lymphocyte ratio in patients with ovarian cancer: A meta-analysis. Eur J Clin Invest 2018; 48(5):12917. [CrossRef] [PubMed]
Timmerman D, Van Calster B, Testa A, Savelli L, Fischerova D, Froyman W et al. Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group. Am J Obstet Gynecol 2016;214(4):424-37. [CrossRef] [PubMed]
Topcu HO, Guzel AI, Ozer I, Kokanali MK, Gokturk U, Muftuoglu KH. Comparison of Neutrophil/Lymphocyte and Platelet/Lymphocyte Ratios for Predicting Malig-nant Potential of Suspicious Ovarian Masses in Gyne-cology Practice. Asian Pac J Cancer Prev 2014;15(15): 6239-41. [CrossRef] [PubMed]
Vernooij F, Heintz AP, Coebergh JW, Massuger LF, Witteveen PO, van der Graaf Y. Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the Netherlands. Gynecol Oncol 2009;112:455-61. [CrossRef] [PubMed]
Zheng H, Tie Y, Wang X, Yang Y, Wei X, Zhao X. Assessment of the diagnostic value of using serum CA125 and GI-RADS system in the evaluation of adnexal masses. Medicine (Baltimore) 2019;98(7): 14577. [CrossRef] [PubMed]